Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacol Ther ; 254: 108592, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38286163

ABSTRACT

Hormone therapy (HT) is important and frequently used both regarding replacement therapy (HRT) and gender affirming therapy (GAHT). While HRT has been effective in addressing symptoms related to hormone shortage, several side effects have been described. In this context, there are some studies that show increased cardiovascular risk. However, there are also studies reporting protective aspects of HT. Nevertheless, the exact impact of HT on cardiovascular risk and the underlying mechanisms remain poorly understood. This article explores the relationship between diverse types of HT and cardiovascular risk, focusing on mechanistic insights of the underlying hormones on platelet and leukocyte function as well as on effects on endothelial and adipose tissue cells.


Subject(s)
Cardiovascular Diseases , Humans , Cardiovascular Diseases/prevention & control , Risk Factors , Hormone Replacement Therapy/adverse effects , Heart Disease Risk Factors , Hormones
2.
Nat Commun ; 14(1): 2404, 2023 04 26.
Article in English | MEDLINE | ID: mdl-37100836

ABSTRACT

Antiplatelet medication is standard of care in acute myocardial infarction (AMI). However, it may have obscured beneficial properties of the activated platelet secretome. We identify platelets as major source of a sphingosine-1-phosphate (S1P) burst during AMI, and find its magnitude to favorably associate with cardiovascular mortality and infarct size in STEMI patients over 12 months. Experimentally, administration of supernatant from activated platelets reduces infarct size in murine AMI, which is blunted in platelets deficient for S1P export (Mfsd2b) or production (Sphk1) and in mice deficient for cardiomyocyte S1P receptor 1 (S1P1). Our study reveals an exploitable therapeutic window in antiplatelet therapy in AMI as the GPIIb/IIIa antagonist tirofiban preserves S1P release and cardioprotection, whereas the P2Y12 antagonist cangrelor does not. Here, we report that platelet-mediated intrinsic cardioprotection is an exciting therapeutic paradigm reaching beyond AMI, the benefits of which may need to be considered in all antiplatelet therapies.


Subject(s)
Blood Platelets , Myocardial Infarction , Humans , Mice , Animals , Myocardial Infarction/drug therapy , Sphingosine , Lysophospholipids/therapeutic use , Myocytes, Cardiac
3.
J Clin Med ; 11(10)2022 May 19.
Article in English | MEDLINE | ID: mdl-35628988

ABSTRACT

In the recently published review titled "Update on Management of Cardiovascular Diseases in Women", Lucà et al. [...].

SELECTION OF CITATIONS
SEARCH DETAIL
...